Clinical Trial Update: A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) [Phase 3]

View source ↗

Summary

Phase 3 trial of TAK-771 in Japanese participants with primary immunodeficiency has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• TAK-771

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED | Results posted: 2024-11-25